Diabetic cardiomyopathy - a distinct disease?

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 3, 2009, Pages 347-360

  Khavandi, Kaivan ^a   Khavandi, Ali ^b   Asghar, Omar ^a   Greenstein, Adam ^a   Withers, Sarah ^a   Heagerty, Anthony M ^a   Malik, Rayaz A ^a  

^a Cardiovascular Research Group   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

cardiomyocyte; cardiomyopathy; diabetes; heart failure

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOSARTAN; NATRIURETIC FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; ROSUVASTATIN; SULFONYLUREA; TEMPOL;

CARDIOMYOPATHY; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GLYCEMIC CONTROL; HEART CATHETERIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREVALENCE; PROGNOSIS; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC DYSFUNCTION; TISSUE DOPPLER IMAGING;

ANIMALS; CALCIUM; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MAGNETIC RESONANCE IMAGING; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE C; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 66449134228     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.10.016     Document Type: Review

References (106)

1. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 9 (1998 Sep) 1414-1431
2. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine 339 4 (1998 Jul 23) 229-234
3. Rubler S., Dlugash J., Yuceoglu Y.Z., et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology 30 6 (1972 Nov 8) 595-602
4. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. American Journal of Cardiology 34 1 (1974 Jul) 29-34
5. Hayat S.A., Patel B., Khattar R.S., et al. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clinical Science 107 6 (2004 Dec) 539-557
6. De Groote P., Lamblin N., Mouquet F., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. European Heart Journal 25 8 (2004 Apr) 656-662
7. Berry C., Brett M., Stevenson K., et al. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart 94 3 (2008 Mar) 296-304
8. Shindler D.M., Kostis J.B., Yusuf S., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. American Journal of Cardiology 77 11 (1996 May 1) 1017-1020
9. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. [see comment]. New England Journal of Medicine 322 22 (1990 May 31) 1561-1566
10. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal 28 20 (2007 Oct) 2539-2550
11. Petrie M.C., Caruana L., Berry C., et al. 'Diastolic heart failure' or heart failure caused by subtle left ventricular systolic dysfunction?. Heart 87 1 (2002 Jan) 29-31
12. Domanski M., Krause-Steinrauf H., Deedwania P., et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology 42 5 (2003 Sep 3) 914-922
13. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. New England Journal of Medicine 355 3 (2006 Jul 20) 260-269
14. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine 355 3 (2006 Jul 20) 251-259
15. Lam C.S.P., Roger V.L., Rodeheffer R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. [erratum appears in Circulation. 2007 May 22;115(20):e535]. Circulation 115 15 (2007 Apr 17) 1982-1990
16. Tribouilloy C., Rusinaru D., Mahjoub H., et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction. A prospective 5-year study. Heart (2008) January 20, 2008:hrt.2007.128769
17. Shishehbor M.H., Hoogwerf B.J., Schoenhagen P., et al. Relation of hemoglobin A1c to left ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart disease. American Journal of Cardiology 91 12 (2003 Jun 15) 1514-1517
18. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. Journal of the American College of Cardiology 48 8 (2006 Oct 17) 1548-1551
19. Poirier P., Bogaty P., Garneau C., et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. [see comment]. Diabetes Care 24 1 (2001 Jan) 5-10
20. Badano L.P., Albanese M.C., De Biaggio P., et al. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. Journal of the American Society of Echocardiography 17 3 (2004 Mar) 253-261
21. Tsang T.S.M., Barnes M.E., Gersh B.J., et al. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. American Journal of Cardiology 90 12 (2002 Dec 15) 1284-1289
22. Di Bonito P., Moio N., Cavuto L., et al. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabetic Medicine 22 12 (2005 Dec) 1720-1725
23. Rademakers F.E. Magnetic resonance imaging in cardiology. Lancet 361 9355 (2003 Feb 1) 359-360
24. Hammer S., van der Meer R.W., Lamb H.J., et al. Short-term Flexibility of Myocardial Triglycerides and Diastolic Function in Patients with Type 2 Diabetes Mellitus. American Journal of Physiology. Endocrinology and Metabolism (2008) July 15, 2008:90413.2008
25. Factor S.M., Okun E.M., and Minase T. Capillary microaneurysms in the human diabetic heart. New England Journal of Medicine 302 7 (1980 Feb 14) 384-388
26. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 22 (2001 Jun 5) 2668-2673
27. Van den Bergh A., Flameng W., and Herijgers P. Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. European Journal of Heart Failure 8 8 (2006 Dec) 777-783
28. Greer J.J.M., Ware D.P., and Lefer D.J. Myocardial infarction and heart failure in the db/db diabetic mouse. American Journal of Physiology - Heart & Circulatory Physiology 290 1 (2006 Jan) H146-H153
29. Boudina S., and Abel E.D. Diabetic cardiomyopathy revisited. Circulation 115 25 (2007 Jun 26) 3213-3223
30. Konduracka E., Gackowski A., Rostoff P., et al. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. [see comment]. European Heart Journal 28 20 (2007 Oct) 2465-2471
31. Seddon M., Looi Y.H., and Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 93 8 (2007 Aug) 903-907
32. Wold L.E., Ceylan-Isik A.F., Fang C.X., et al. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radical Biology & Medicine 40 8 (2006 Apr 15) 1419-1429
33. Liang Q., Carlson E.C., Donthi R.V., et al. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51 1 (2002 Jan) 174-181
34. Cai L., Wang Y., Zhou G., et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. Journal of the American College of Cardiology 48 8 (2006 Oct 17) 1688-1697
35. Ye G., Metreveli N.S., Donthi R.V., et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53 5 (2004 May) 1336-1343
36. Gao W.D., Liu Y., and Marban E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. Circulation 94 10 (1996 Nov 15) 2597-2604
37. Li J.-M., Gall N.P., Grieve D.J., et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40 4 (2002 Oct) 477-484
38. Ritchie R.H., Quinn J.M., Cao A.H., et al. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. Journal of Molecular & Cellular Cardiology 42 6 (2007 Jun) 1119-1128
39. Tesfamariam B., Brown M.L., and Cohen R.A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. Journal of Clinical Investigation 87 5 (1991 May) 1643-1648
40. Duncan E.R., Walker S.J., Ezzat V.A., et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. American Journal of Physiology - Endocrinology & Metabolism 293 5 (2007 Nov) E1311-E1319
41. Hornig B., Arakawa N., Kohler C., et al. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 97 4 (1998 Feb 3) 363-368
42. MacCarthy P.A., Grieve D.J., Li J.M., et al. Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104 24 (2001 Dec 11) 2967-2974
43. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. [see comment]. New England Journal of Medicine 342 3 (2000 Jan 20) 154-160
44. Yang Z., Zingarelli B., and Szabo C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. Shock 13 1 (2000 Jan) 60-66
45. Du X., Matsumura T., Edelstein D., et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. [see comment]. Journal of Clinical Investigation 112 7 (2003 Oct) 1049-1057
46. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News & Perspectives 15 (2002) 197-205
47. Minchenko A.G., Stevens M.J., White L., et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB Journal 17 11 (2003 Aug) 1514-1516
48. Chiu J., Farhangkhoee H., Xu B.Y., et al. PARP mediates structural alterations in diabetic cardiomyopathy. Journal of Molecular and Cellular Cardiology 45 3 (2008 Sep) 385-393
49. Soriano F.G., Pacher P., Mabley J., et al. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circulation Research 89 8 (2001 Oct 12) 684-691
50. Bowling N., Walsh R.A., Song G., et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99 3 (1999 Jan 26) 384-391
51. Way K.J., Isshiki K., Suzuma K., et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51 9 (2002 Sep) 2709-2718
52. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 6 (1998 Jun) 859-866
53. Braz J.C., Gregory K., Pathak A., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. [see comment]. Nature Medicine 10 3 (2004 Mar) 248-254
54. Wakasaki H., Koya D., Schoen F.J., et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America 94 17 (1997 Aug 19) 9320-9325
55. Topham M.K., and Prescott S.M. Diacylglycerol kinases: regulation and signaling roles. Thrombosis & Haemostasis 88 6 (2002 Dec) 912-918
56. Harada M., Takeishi Y., Arimoto T., et al. Diacylglycerol kinase zeta attenuates pressure overload-induced cardiac hypertrophy. Circulation Journal 71 2 (2007 Feb) 276-282
57. Bilim O., Takeishi Y., Kitahara T., et al. Diacylglycerol kinase zeta inhibits myocardial atrophy and restores cardiac dysfunction in streptozotocin-induced diabetes mellitus. Cardiovascular Diabetology 7 (2008) 2
58. Xia Z., Kuo K.-H., Nagareddy P.R., et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovascular Research 73 4 (2007 Mar 1) 770-782
59. Hambleton M., Hahn H., Pleger S.T., et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 114 6 (2006 Aug 8) 574-582
60. Arikawa E., Ma R.C.W., Isshiki K., et al. Effects of insulin replacements, inhibitors of angiotensin, and PKCbeta's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes 56 5 (2007 May) 1410-1420
61. Bers D.M. Cardiac excitation-contraction coupling. Nature 415 6868 (2002 Jan 10) 198-205
62. Trost S.U., Belke D.D., Bluhm W.F., et al. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51 4 (2002 Apr) 1166-1171
63. Hattori Y., Matsuda N., Kimura J., et al. Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload. Journal of Physiology 527 Pt 1 (2000 Aug 15) 85-94
64. Pereira L., Matthes J., Schuster I., et al. Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55 3 (2006 Mar) 608-615
65. Golfman L., Dixon I.M., Takeda N., et al. Cardiac sarcolemmal Na(+)-Ca2+ exchange and Na(+)-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats. Molecular & Cellular Biochemistry 188 1-2 (1998 Nov) 91-101
66. Vetter R., Rehfeld U., Reissfelder C., et al. Transgenic overexpression of the sarcoplasmic reticulum Ca2 + ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB Journal 16 12 (2002 Oct) 1657-1659
67. Yaras N., Bilginoglu A., Vassort G., et al. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. American Journal of Physiology - Heart & Circulatory Physiology 292 2 (2007 Feb) H912-H920
68. Jweied E.E., McKinney R.D., Walker L.A., et al. Depressed cardiac myofilament function in human diabetes mellitus. American Journal of Physiology - Heart & Circulatory Physiology 289 6 (2005 Dec) H2478-H2483
69. Qin D., Huang B., Deng L., et al. Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy. Biochemical & Biophysical Research Communications 283 3 (2001 May 11) 549-553
70. Cooper G.J.S., Phillips A.R.J., Choong S.Y., et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53 9 (2004 Sep) 2501-2508
71. Dostal D.E., Rothblum K.N., Chernin M.I., et al. Intracardiac detection of angiotensinogen and renin: a localized renin-angiotensin system in neonatal rat heart. American Journal of Physiology 263 4 Pt 1 (1992 Oct) C838-C850
72. Privratsky J.R., Wold L.E., Sowers J.R., et al. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42 2 (2003 Aug) 206-212
73. Raimondi L., De Paoli P., Mannucci E., et al. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 53 7 (2004 Jul) 1927-1933
74. Fiordaliso F., Cuccovillo I., Bianchi R., et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sciences 79 2 (2006 Jun 6) 121-129
75. Liu X., Suzuki H., Sethi R., et al. Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Annals of the New York Academy of Sciences 1084 (2006 Nov) 141-154
76. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. [see comment][erratum appears in Lancet 2000 Sep 2;356(9232):860]. Lancet 355 9200 (2000 Jan 22) 253-259
77. Kajstura J., Fiordaliso F., Andreoli A.M., et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50 6 (2001 Jun) 1414-1424
78. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. [erratum appears in Circulation 2001 Jan 23;103(3):476]. Circulation 102 22 (2000 Nov 28) 2700-2706
79. McEwan P.E., Gray G.A., Sherry L., et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 98 24 (1998 Dec 15) 2765-2773
80. Neumann S., Huse K., Semrau R., et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 39 3 (2002 Mar 1) 756-760
81. Liu Y., Cox S.R., Morita T., et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circulation Research 77 3 (1995 Sep) 638-643
82. Richard D.E., Berra E., and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. Journal of Biological Chemistry 275 35 (2000 Sep 1) 26765-26771
83. Abaci A., Oguzhan A., Kahraman S., et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99 17 (1999 May 4) 2239-2242
84. Shinohara K., Shinohara T., Mochizuki N., et al. Expression of vascular endothelial growth factor in human myocardial infarction. Heart & Vessels 11 3 (1996) 113-122
85. Chou E., Suzuma I., Way K.J., et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105 3 (2002 Jan 22) 373-379
86. Emoto M., Anno T., Sato Y., et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 50 5 (2001 May) 1166-1170
87. Ebrahimian T.G., Heymes C., You D., et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. American Journal of Pathology 169 2 (2006 Aug) 719-728
88. Jesmin S., Zaedi S., Shimojo N., et al. Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. American Journal of Physiology - Endocrinology & Metabolism 292 4 (2007 Apr) E1030-E1040
89. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. [see comment][erratum appears in 2000 May 4;342(18):1376]. New England Journal of Medicine 342 3 (2000 Jan 20) 145-153
90. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. [see comment] [summary for patients in J Card Fail. 2002 Apr;8(2):56-8; PMID: 12016625]. New England Journal of Medicine 345 23 (2001 Dec 6) 1667-1675
91. Haas S.J., Vos T., Gilbert R.E., et al. Are [beta]-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. American Heart Journal 146 5 (2003) 848-853
92. Werner C.M., and Bohm M. Review: the therapeutic role of RAS blockade in chronic heart failure. Therapeutic Advances in Cardiovascular Disease 2 3 (2008) 167-177
93. Warner Jr. J.G., Metzger D.C., Kitzman D.W., et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. Journal of the American College of Cardiology 33 6 (1999 May) 1567-1572
94. Pieske B.A., and Wachter R.B. Impact of diabetes and hypertension on the heart. Current Opinion in Cardiology 23 4 (July 2008) 340-349
95. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. [see comment] [erratum appears in Lancet 1999 Aug 14;354(9178):602]. Lancet 352 9131 (1998 Sep 12) 837-853
96. Group UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 7160 (1998) 703-713
97. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein H.C., Miller M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. [see comment]. New England Journal of Medicine 358 24 (2008 Jun 12) 2545-2559
98. Group AC, Patel A., MacMahon S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. [see comment]. New England Journal of Medicine 358 24 (2008 Jun 12) 2560-2572
99. Ryden L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). [see comment]. European Heart Journal 28 1 (2007 Jan) 88-136
100. Sasso F.C., Carbonara O., Cozzolino D., et al. Effects of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients: a radionuclide ventriculographic study. Journal of the American College of Cardiology 36 1 (2000 Jul) 219-226
101. Horio T., Suzuki M., Suzuki K., et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. American Journal of Hypertension 18 7 (2005 Jul) 949-957
102. Cobitz A., Zambanini A., Sowell M., et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiology and Drug Safety 17 8 (2008) 769-781
103. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [see comment] [erratum appears in N Engl J Med. 2007 Jul 5;357(1):100]. New England Journal of Medicine 356 24 (2007 Jun 14) 2457-2471
104. Investigators D.T., Dagenais G.R., Gerstein H.C., et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31 5 (2008 May) 1007-1014
105. Ramasubbu K., Estep J., White D.L., et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. Journal of the American College of Cardiology 51 4 (2008 Jan 29) 415-426
106. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. [see comment]. New England Journal of Medicine 357 22 (2007 Nov 29) 2248-2261